Lyra Therapeutics
LYRA · NASDAQ
$0.19−$0.16 (−45.71%)TodayMarket closed ·
Prev close $0.35
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 23.1% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q3 FY25 | -$5.36 | -$3.38 | +36.9% |
| Q2 FY25 | -$6.14 | -$5.51 | +10.3% |
| Q1 FY25 | -$6.97 | -$6.00 | +13.9% |
| Q4 FY24 | -$6.12 | -$8.00 | −30.7% |
| Q3 FY24 | -$11.63 | -$9.00 | +22.6% |
| Q2 FY24 | -$16.73 | -$37.00 | −121.2% |
| Q1 FY24 | -$13.36 | -$17.50 | −31.0% |
| Q4 FY23 | -$16.07 | -$11.00 | +31.5% |
Earnings calls
- Special Call - Lyra Therapeutics, Inc.
- Special Call - Lyra Therapeutics, Inc.
- Bank of America Securities 2023 Healthcare Conference
- Bank of America 2022 Healthcare Conference
- LYRA - Earnings call Q3 2021
- Special Call - Lyra Therapeutics, Inc.
- Chronic Rhinosinusitis (CRS) Key Opinion Leader Event
- LYRA - Earnings call Q2 2021
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.